Nutrition researchers have spent decades building a case for a plant that most North Americans overlook entirely. Guava ...

MSD's oral HIF-2 alpha inhibitor Welireg has a third FDA approval, becoming the first oral treatment for a rare form of solid tumour that affects around 2,000 people in the US each year. The green ...

98% of drugs do not reach the brain, as the blood–brain barrier (BBB) separates peripheral blood circulation from the central nervous system (CNS). Galmed has developed, in collaboration with Barcode ...

Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United ...

Sasineprocel’s encouraging Phase I/IIa data positions autologous iPSC-derived dopaminergic neuron therapy as a potential monotherapy challenger in Parkinson’s disease (PD), signaling a shift toward ...

A brand-new event has just launched in the renowned World ADC Series – the inaugural ADC Payload Summit is taking place this May in Boston (21-23)! The ADC payload landscape is shifting rapidly.

The standard therapy of Parkinson’s disease consists in supplementing the depleted dopamine with oral levodopa. The disadvantages of the levodopa monotherapy – comparable to other dopaminergic ...